Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
复制标题
DOI:
10.1371/journal.pone.0195850
复制
发表时间:
2018
期刊:
影响因子:
3.7
通讯作者:
Datson NA
中科院分区:
文献类型:
--
作者:
Beekman C;Janson AA;Baghat A;van Deutekom JC;Datson NA
Duchenne muscular dystrophy (DMD) is a neuromuscular disease characterized by progressive weakness of the skeletal and cardiac muscles. This X-linked disorder is caused by open reading frame disrupting mutations in the DMD gene, resulting in strong reduction or complete absence of dystrophin protein. In order to use dystrophin as a supportive or even surrogate biomarker in clinical studies on investigational drugs aiming at correcting the primary cause of the disease, the ability to reliably quantify dystrophin expression in muscle biopsies of DMD patients pre- and post-treatment is essential. Here we demonstrate the application of the ProteinSimple capillary immunoassay (Wes) method, a gel- and blot-free method requiring less sample, antibody and time to run than conventional Western blot assay. We optimized dystrophin quantification by Wes using 2 different antibodies and found it to be highly sensitive, reproducible and quantitative over a large dynamic range. Using a healthy control muscle sample as a reference and α-actinin as a protein loading/muscle content control, a panel of skeletal muscle samples consisting of 31 healthy controls, 25 Becker Muscle dystrophy (BMD) and 17 DMD samples was subjected to Wes analysis. In healthy controls dystrophin levels varied 3 to 5-fold between the highest and lowest muscle samples, with the reference sample representing the average of all 31 samples. In BMD muscle samples dystrophin levels ranged from 10% to 90%, with an average of 33% of the healthy muscle average, while for the DMD samples the average dystrophin level was 1.3%, ranging from 0.7% to 7% of the healthy muscle average. In conclusion, Wes is a suitable, efficient and reliable method for quantification of dystrophin expression as a biomarker in DMD clinical drug development.
登录
查看更多内容
影响因子:
14.5
作者:
Anthony, Karen;Cirak, Sebahattin;Muntoni, Francesco
通讯作者:
Muntoni, Francesco
影响因子:
5
作者:
Taylor, L. E.;Kaminoh, Y. J.;Flanigan, K. M.
通讯作者:
Flanigan, K. M.
影响因子:
168.9
作者:
Cirak, Sebahattin;Arechavala-Gomeza, Virginia;Guglieri, Michela;Feng, Lucy;Torelli, Silvia;Anthony, Karen;Abbs, Stephen;Garralda, Maria Elena;Bourke, John;Wells, Dominic J.;Dickson, George;Wood, Matthew J. A.;Wilton, Steve D.;Straub, Volker;Kole, Ryszard;Shrewsbury, Stephen B.;Sewry, Caroline;Morgan, Jennifer E.;Bushby, Kate;Muntoni, Francesco
通讯作者:
Muntoni, Francesco
DOI:
10.1083/jcb.115.2.411
发表时间:
1991-10
期刊:
The Journal of cell biology
影响因子:
--
作者:
Byers TJ;Kunkel LM;Watkins SC
通讯作者:
Watkins SC
影响因子:
2.9
作者:
Chen JQ;Heldman MR;Herrmann MA;Kedei N;Woo W;Blumberg PM;Goldsmith PK
通讯作者:
Goldsmith PK